Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

Akrotome Imaging Receives $1.7M Grant from NIH to Advance Research for Technology that Sheds a “Light” on Cancer

Akrotome Imaging Inc., a Cleveland-based medical imaging technology company, has received a major award from the National Institutes of Health (NIH) to complete development and commercialization of its leading-edge imaging platform.

Isotope Technologies Garching GmbH Announces In-licensing of DOTA-Zoledronate for Bone Targeted Radionuclide Theranostics of Osseous Metastases

The ITM Group announced today that its subsidiary ITG GmbH has successfully in-licensed DOTA-Zoledronate, a next generation theranostic agent for Bone Targeted Radionuclide Therapy and Diagnostics in patients suffering from bone metastases. 

NHS pushes for major multi-site genomics project

The United Kingdom’s National Health Service (NHS) is embarking on an ambitious gene-sequencing project with 11 genomics institutions in England. The objective is to find targeted treatments for a spectrum of illnesses.

Thumbnail

Zecotek settles patent suit against Philips, Saint Gobain

Singapore-based Zecotek Photonics, makers of industrial imaging technologies, announced today that the company has settled a lawsuit brought against Philips and Saint Gobain over patent infringement regarding new PET detector technology.

Quantitative FET-PET makes the grade for advanced glioma

High-grade astrocytoma is a particularly aggressive form of glioma. Parameters of PET imaging such as the minimal time-to-peak could help clinicians narrow in on the best line of treatment for each patient, according to a study published Dec. 23 in the Journal of Nuclear Medicine.

Hedge fund CEO gifts $15M for Alzheimer’s institute

The chief executive officer of Park Avenue hedge fund Third Point, is set to donate $15 million to Mount Sinai Hospital and the Icahn School of Medicine in New York City for a new research institute devoted to studying Alzheimer’s disease.

Thumbnail

Big brain gene could inform treatments for neurodevelopmental disorders

One gene in particular could be the key master for proper brain development, researchers from the Agency for Science, Technology and Researc

Thumbnail

FDG PET/ CT predicts survival in non-small cell lung cancer patients

A quantitative PET measurement known as total lesion glycolysis could help clinicians make informed prognoses for patients with a stage of non-small lung cancer, according to a study published online Dec. 18 in the Journal of Nuclear Medicine.